Cargando…

Uveitis in spondyloarthritis

Uveitis is the most frequent extra-articular manifestation of axial spondyloarthritis (SpA), occurring in up to one-third of the patients. In the majority of patients, uveitis is acute, anterior and unilateral and presents with photosensitivity, sudden onset of pain and blurred vision. Topical stero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rademacher, Judith, Poddubnyy, Denis, Pleyer, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Extra-Articular Manifestations and Comorbidities in Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488890/ https://www.ncbi.nlm.nih.gov/pubmed/32963592 http://dx.doi.org/10.1177/1759720X20951733

Ejemplares similares

Skin manifestations in spondyloarthritis
por: Meier, Katharina, et al.
Publicado: (2020)

The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study
por: Redeker, Imke, et al.
Publicado: (2020)

IBD considerations in spondyloarthritis
por: Di Jiang, Caroline, et al.
Publicado: (2020)

Multidisciplinary working in the management of axial and peripheral spondyloarthritis
por: Gudu, Tania, et al.
Publicado: (2020)

Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis
por: Chung, Ho Yin, et al.
Publicado: (2020)

Mast cells in spondyloarthritis, more than simple inflammatory bystanders?
por: Polivka, Laura, et al.
Publicado: (2020)

Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs
por: Chan, Shirley Chiu Wai, et al.
Publicado: (2021)

Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
por: Parkinson, Joel T., et al.
Publicado: (2020)

Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features?
por: Clunie, Gavin, et al.
Publicado: (2020)

Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis
por: Ladehesa-Pineda, María Lourdes, et al.
Publicado: (2020)

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system
por: How Shing Koy, Elsa, et al.
Publicado: (2021)

Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus
por: Fragoulis, George E., et al.
Publicado: (2020)

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
por: Karmacharya, Paras, et al.
Publicado: (2021)

Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study
por: Siao, Wun-Zhih, et al.
Publicado: (2021)

Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis
por: Lam, Steven H., et al.
Publicado: (2021)

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2021)

Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
por: Torgutalp, Murat, et al.
Publicado: (2022)

The frequency of uveitis in patients with adult versus childhood spondyloarthritis
por: Turk, Matthew, et al.
Publicado: (2020)

Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021)

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
por: Poddubnyy, Denis, et al.
Publicado: (2018)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Prevalence of axial spondyloarthritis in patients with acute anterior uveitis: a cross-sectional study utilising MRI
por: Sykes, Mark P, et al.
Publicado: (2018)

Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis
por: Hoppe, Berthold, et al.
Publicado: (2021)

Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
por: Lindström, Ulf, et al.
Publicado: (2021)

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2020)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021)

Comorbidity management in spondyloarthritis
por: López-Medina, Clementina, et al.
Publicado: (2020)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
por: Deodhar, Atul, et al.
Publicado: (2019)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2022)

Peripheral spondyloarthritis: a neglected entity—state of the art
por: Carron, Philippe, et al.
Publicado: (2020)

Biomechanics in the onset and severity of spondyloarthritis: a force to be reckoned with
por: Iyer, Priyanka, et al.
Publicado: (2023)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis
por: Perrotta, Fabio Massimo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hfi3s416abgmaolkv6inmiq8qb